Acumen pharmaceuticals to participate in the stifel 2024 cns days

Charlottesville, va., march 12, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat as part of the stifel 2024 cns days on tuesday, march 19, 2024, at 12:00 p.m. et.
ABOS Ratings Summary
ABOS Quant Ranking